Cargando…

Screening of hub genes and evaluation of the growth regulatory role of CD44 in metastatic prostate cancer

Prostate cancer (PCa) is the most common cancer type in men worldwide. Currently, the management of metastatic PCa (mPCa) remains a challenge to urologists. The analysis of hub genes and pathways may facilitate the understanding of the molecular mechanism of PCa. In the present study, to identify th...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Junhao, Chen, Zhi, Li, Zuan, Nong, Deyong, Li, Ximing, Huang, Guihai, Hao, Nan, Liang, Jianbo, Li, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317150/
https://www.ncbi.nlm.nih.gov/pubmed/34296309
http://dx.doi.org/10.3892/or.2021.8147
_version_ 1783730014731108352
author Lin, Junhao
Chen, Zhi
Li, Zuan
Nong, Deyong
Li, Ximing
Huang, Guihai
Hao, Nan
Liang, Jianbo
Li, Wei
author_facet Lin, Junhao
Chen, Zhi
Li, Zuan
Nong, Deyong
Li, Ximing
Huang, Guihai
Hao, Nan
Liang, Jianbo
Li, Wei
author_sort Lin, Junhao
collection PubMed
description Prostate cancer (PCa) is the most common cancer type in men worldwide. Currently, the management of metastatic PCa (mPCa) remains a challenge to urologists. The analysis of hub genes and pathways may facilitate the understanding of the molecular mechanism of PCa. In the present study, to identify the hub genes in the mPCa, the three datasets GSE3325, GSE6919 and GSE38241 were downloaded from the platform of the Gene Expression Omnibus and function enrichment analysis of differentially expressed genes (DEGs) was performed. A total of 168 DEGs were obtained and the DEGs were significantly enriched in ‘cell junction’ and ‘cell adhesion’, among others. The Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis demonstrated that DEGs were enriched in three pathways including ‘focal adhesion’, ‘renal cell carcinoma’ and ‘Hippo signaling pathway’. The results of the protein-protein interaction network revealed that the hub genes in mPCa were separately PTEN, Rac GTPase-activating protein 1, protein regulator of cytokinesis 1, PDZ binding kinase, centromere-associated protein E, NUF2 component of NDC80 kinetochore complex, TPX2 microtubule nucleation factor, SOX2, CD44 and ubiquitin-like with PHD and ring finger domains 1. As a hub gene, CD44 was differentially expressed in PCa, as determined by Oncomine analysis. Further experiments in vivo demonstrated that SB-3CT, a selective matrix metalloproteinase inhibitor that has been reported to block CD44 cleavage and inhibit the downstream signaling pathway, suppressed the tumorigenicity of PCa cells by decreasing the expression levels of pyruvate dehydrogenase kinase 1 and 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4. Moreover, the combination therapy with SB-3CT and docetaxel was more effective in inhibiting PCa compared with monotherapy. In conclusion, the identification of DEGs and the in vivo experimental results helped to elucidate the molecular mechanisms of PCa and provided a potential strategy for the treatment of PCa.
format Online
Article
Text
id pubmed-8317150
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-83171502021-07-31 Screening of hub genes and evaluation of the growth regulatory role of CD44 in metastatic prostate cancer Lin, Junhao Chen, Zhi Li, Zuan Nong, Deyong Li, Ximing Huang, Guihai Hao, Nan Liang, Jianbo Li, Wei Oncol Rep Articles Prostate cancer (PCa) is the most common cancer type in men worldwide. Currently, the management of metastatic PCa (mPCa) remains a challenge to urologists. The analysis of hub genes and pathways may facilitate the understanding of the molecular mechanism of PCa. In the present study, to identify the hub genes in the mPCa, the three datasets GSE3325, GSE6919 and GSE38241 were downloaded from the platform of the Gene Expression Omnibus and function enrichment analysis of differentially expressed genes (DEGs) was performed. A total of 168 DEGs were obtained and the DEGs were significantly enriched in ‘cell junction’ and ‘cell adhesion’, among others. The Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis demonstrated that DEGs were enriched in three pathways including ‘focal adhesion’, ‘renal cell carcinoma’ and ‘Hippo signaling pathway’. The results of the protein-protein interaction network revealed that the hub genes in mPCa were separately PTEN, Rac GTPase-activating protein 1, protein regulator of cytokinesis 1, PDZ binding kinase, centromere-associated protein E, NUF2 component of NDC80 kinetochore complex, TPX2 microtubule nucleation factor, SOX2, CD44 and ubiquitin-like with PHD and ring finger domains 1. As a hub gene, CD44 was differentially expressed in PCa, as determined by Oncomine analysis. Further experiments in vivo demonstrated that SB-3CT, a selective matrix metalloproteinase inhibitor that has been reported to block CD44 cleavage and inhibit the downstream signaling pathway, suppressed the tumorigenicity of PCa cells by decreasing the expression levels of pyruvate dehydrogenase kinase 1 and 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4. Moreover, the combination therapy with SB-3CT and docetaxel was more effective in inhibiting PCa compared with monotherapy. In conclusion, the identification of DEGs and the in vivo experimental results helped to elucidate the molecular mechanisms of PCa and provided a potential strategy for the treatment of PCa. D.A. Spandidos 2021-09 2021-07-19 /pmc/articles/PMC8317150/ /pubmed/34296309 http://dx.doi.org/10.3892/or.2021.8147 Text en Copyright: © Lin et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Lin, Junhao
Chen, Zhi
Li, Zuan
Nong, Deyong
Li, Ximing
Huang, Guihai
Hao, Nan
Liang, Jianbo
Li, Wei
Screening of hub genes and evaluation of the growth regulatory role of CD44 in metastatic prostate cancer
title Screening of hub genes and evaluation of the growth regulatory role of CD44 in metastatic prostate cancer
title_full Screening of hub genes and evaluation of the growth regulatory role of CD44 in metastatic prostate cancer
title_fullStr Screening of hub genes and evaluation of the growth regulatory role of CD44 in metastatic prostate cancer
title_full_unstemmed Screening of hub genes and evaluation of the growth regulatory role of CD44 in metastatic prostate cancer
title_short Screening of hub genes and evaluation of the growth regulatory role of CD44 in metastatic prostate cancer
title_sort screening of hub genes and evaluation of the growth regulatory role of cd44 in metastatic prostate cancer
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317150/
https://www.ncbi.nlm.nih.gov/pubmed/34296309
http://dx.doi.org/10.3892/or.2021.8147
work_keys_str_mv AT linjunhao screeningofhubgenesandevaluationofthegrowthregulatoryroleofcd44inmetastaticprostatecancer
AT chenzhi screeningofhubgenesandevaluationofthegrowthregulatoryroleofcd44inmetastaticprostatecancer
AT lizuan screeningofhubgenesandevaluationofthegrowthregulatoryroleofcd44inmetastaticprostatecancer
AT nongdeyong screeningofhubgenesandevaluationofthegrowthregulatoryroleofcd44inmetastaticprostatecancer
AT liximing screeningofhubgenesandevaluationofthegrowthregulatoryroleofcd44inmetastaticprostatecancer
AT huangguihai screeningofhubgenesandevaluationofthegrowthregulatoryroleofcd44inmetastaticprostatecancer
AT haonan screeningofhubgenesandevaluationofthegrowthregulatoryroleofcd44inmetastaticprostatecancer
AT liangjianbo screeningofhubgenesandevaluationofthegrowthregulatoryroleofcd44inmetastaticprostatecancer
AT liwei screeningofhubgenesandevaluationofthegrowthregulatoryroleofcd44inmetastaticprostatecancer